Evidence suggests that the improvement intercytex hair loss in hair count reported after 1 year is maintained during 2 years' treatment. propecia In men with vertex hair loss, global photographs sho improvement in hair growth ortho tri cyclen low hair loss in 48% of Finasteride ( Propecia ) recipients at 1 year and in 66% at 2 years compared with 7% of placebo recipients at each time point. Most events hair loss alopecia propecia were of mild to moderate severity. A review of its use in male pattern hair loss.The 5alpha-reductase inhibitor Finasteride ( Propecia ) blocks the topical finasteride conversion of testosterone to dihydrotestosterone (DHT), the androgen responsible for hair regrowth male pattern hair loss (androgenetic alopecia) in genetically predisposed men. The overall incidence of sexual function disorders, comprising decreased libido, ejaculation disorder and erectile hair loss dysfunction, was significantly greater in Finasteride ( Propecia ) than placebo recipients (3.8 vs 2.1%). Oral Finasteride ( Propecia ) promotes scalp hair growth and prevents further hair loss in a significant proportion hair loss of men with male pattern hair loss. All sexual adverse events were reversed on discontinuation of therapy and many resolved baldness in patients who continued therapy.
Its role relative to topical minoxidil has yet to be determined.. Furthermore, hair counts in these men sho that 83% of Finasteride ( Propecia ) versus 28% of placebo recipients had no further hair loss compared with baseline after 2 years. With its generally good tolerability profile, Finasteride ( Propecia ) is a new approach to the management of this condition, for which treatment options are few. No other drug-related events were reported with an incidence > hair regrowth or 1% in patients receiving Finasteride ( Propecia ). Therapeutic dosages of Finasteride ( Propecia ) are generally well tolerated.
Oral Finasteride ( Propecia ) is contraindicated in pregnant women because of the risk of hypospadias in male fetuses. The clinical efficacy of oral Finasteride ( Propecia ) has not yet been compared with that of topical minoxidil, the only other drug used clinically in patients with male pattern hair loss. Results of phase III clinical studies in 1879 men have shown that oral Finasteride ( Propecia ) 1 mg/day promotes hair growth and prevents further hair loss in a significant proportion of men with male pattern hair loss. In phase III studies, 7.7% of patients receiving Finasteride ( Propecia ) 1 mg/day compared with 7.0% of those receiving placebo reported treatment-related adverse events.
.